Elekta

Legal Proceedings Report • Oct 31, 2016

USITC publishes initial determination in litigation dispute

STOCKHOLM, October 31, 2016 – An Administrative Law Judge of the United States International Trade Commission (USITC) issued an initial determination (a first decision) on October 27 in a litigation dispute with Varian Medical Systems.

The judge dismissed Varian's infringement claims on patents related to imaging enhanced radiotherapy and declared them not infringed by Elekta or invalid due to prior art incorporated in patents exclusively licensed by Elekta.

He further stated that certain parts of Elekta's radiotherapy solutions are violating patents owned by Varian, predominantly related to algorithms used in treatment planning software. The judge's initial determination is being analyzed and several grounds have been identified on which to seek review of this initial determination before the USITC.

Elekta has previously filed parallel proceedings at the US Patent and Trademark Office, which have been instituted, to declare these patents invalid. Preliminary analysis is that there is a reasonable likelihood of success in these cases.

This initial determination of the USITC will be subject to procedural reviews within the USITC before any final determination is reached, which will likely last until the end of Elekta's fiscal year 2016/2017.

#

For further information, please contact:

Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com Time zone: CET: Central European Time

Johan Andersson, Director Investor Relations, Elekta AB Tel: +46 8 587 25 415, e-mail: johan.andersson@elekta.com Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on October 31, 2016.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resourceefficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.